The UK and US have concluded a significant trade agreement that will maintain zero duties on British pharmaceutical exports entering the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to raise expenditure on drugs through the National Health Service (NHS). This move secures that duties on these vital goods will remain at zero for a period of 36 months.
This deal follows previous statements to significantly raise duties on patented pharmaceutical products, with potential rates mentioned as high as 100%.
"This arrangement with the UK strengthens the international landscape for new treatments and establishes much-needed equity to American-British drug exports," a statement said.
Commercial Impact
Drugs represent one of the the United Kingdom's most significant export categories to the US, which is clearly the biggest destination for large UK drugmakers.
Statistics reveal that in the year prior to last September, the UK shipped medicines valued at billions to the US. This figure represented nearly one-fifth of all goods exports in that timeframe.
"This agreement safeguards jobs, increases investment and paves the way for the UK to emerge as a global hub for biotech and pharma," a minister commented.
Specific NHS Changes
The pact includes several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be too expensive by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to stay within budget will be limited at 15%. Last year, refunds were more than 20%.
Broader Context
The pact follows a long-running dispute between the drug companies and the British authorities over medicine costs and NHS adoption.
The disagreement were exacerbated by assertions that American customers were paying a premium for the equivalent treatments than people in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while major expansions have been announced toward US facilities.
One official stated that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
